Related Experiment Video
Updated: Jun 12, 2025
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Potential promising of synthetic lethality in cancer research and treatment
Mohsen Karami Fath1, Behnam Najafiyan2, Reza Morovatshoar3
1Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
Abstract:
Cancer is a complex disease driven by multiple genetic changes, including mutations in oncogenes, tumor suppressor genes, DNA repair genes, and genes involved in cancer metabolism. Synthetic lethality (SL) is a promising approach in cancer research and treatment, where the simultaneous dysfunction of specific genes or pathways causes cell death. By targeting vulnerabilities created by these dysfunctions, SL therapies selectively kill cancer cells while sparing normal cells. SL therapies, such as PARP inhibitors, WEE1 inhibitors, ATR and ATM inhibitors, and DNA-PK inhibitors, offer a distinct approach to cancer treatment compared to conventional targeted therapies. Instead of directly inhibiting specific molecules or pathways, SL therapies exploit genetic or molecular vulnerabilities in cancer cells to induce selective cell death, offering benefits such as targeted therapy, enhanced treatment efficacy, and minimized harm to healthy tissues. SL therapies can be personalized based on each patient's unique genetic profile and combined with other treatment modalities to potentially achieve synergistic effects. They also broaden the effectiveness of treatment across different cancer types, potentially overcoming drug resistance and improving patient outcomes. This review offers an overview of the current understanding of SL mechanisms, advancements, and challenges, as well as the preclinical and clinical development of SL. It also discusses new directions and opportunities for utilizing SL in targeted therapy for anticancer treatment.
Insights
Synthetic lethality (SL) targets cancer vulnerabilities by exploiting simultaneous gene or pathway dysfunction for selective cell death. This approach offers personalized, effective anticancer treatments with minimized harm to healthy tissues.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer arises from multiple genetic alterations affecting oncogenes, tumor suppressors, DNA repair, and metabolism.
- Synthetic lethality (SL) presents a novel therapeutic strategy exploiting gene/pathway co-dependencies for cancer cell death.
- Existing targeted therapies often face limitations, necessitating innovative treatment modalities.
Purpose of the Study:
- To provide a comprehensive overview of synthetic lethality (SL) mechanisms and applications in cancer.
- To review the advancements and challenges in preclinical and clinical development of SL-based therapies.
- To explore future directions and opportunities for SL in targeted anticancer treatment.
Main Methods:
- Review of current literature on synthetic lethality (SL) in cancer research.
- Analysis of preclinical and clinical data for SL-targeting drugs (e.g., PARP, WEE1, ATR, ATM, DNA-PK inhibitors).
- Discussion of genetic vulnerabilities and personalized treatment strategies in oncology.
Main Results:
- SL therapies selectively eliminate cancer cells by exploiting genetic vulnerabilities, sparing normal tissues.
- SL approaches, including PARP, WEE1, ATR, ATM, and DNA-PK inhibitors, offer enhanced efficacy and reduced toxicity.
- Personalized SL treatments, combined with other modalities, show potential for synergistic effects and overcoming drug resistance.
Conclusions:
- Synthetic lethality is a promising therapeutic paradigm for targeted cancer treatment.
- SL therapies offer a distinct advantage over conventional treatments by exploiting cancer-specific vulnerabilities.
- Further research into SL mechanisms and clinical development holds significant potential for improving patient outcomes across various cancer types.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:26Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...